RS59774B1 - Vakcina zasnovana na rekombinantnom jeryl lynn 2 virusu zauški - Google Patents

Vakcina zasnovana na rekombinantnom jeryl lynn 2 virusu zauški

Info

Publication number
RS59774B1
RS59774B1 RS20200031A RSP20200031A RS59774B1 RS 59774 B1 RS59774 B1 RS 59774B1 RS 20200031 A RS20200031 A RS 20200031A RS P20200031 A RSP20200031 A RS P20200031A RS 59774 B1 RS59774 B1 RS 59774B1
Authority
RS
Serbia
Prior art keywords
mumps virus
based vaccine
jeryl lynn
recombinant mumps
virus jeryl
Prior art date
Application number
RS20200031A
Other languages
English (en)
Inventor
Reinhard Glueck
Viviana Giannino
Gaurav Gupta
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of RS59774B1 publication Critical patent/RS59774B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18751Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20200031A 2015-03-27 2016-03-28 Vakcina zasnovana na rekombinantnom jeryl lynn 2 virusu zauški RS59774B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1055MU2015 2015-03-27
EP16721253.9A EP3274447B1 (en) 2015-03-27 2016-03-28 Recombinant mumps virus jeryl lynn 2 based vaccine
PCT/IN2016/000074 WO2016157208A1 (en) 2015-03-27 2016-03-28 Recombinant mumps virus jeryl lynn 2 based vaccine

Publications (1)

Publication Number Publication Date
RS59774B1 true RS59774B1 (sr) 2020-02-28

Family

ID=55948921

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200031A RS59774B1 (sr) 2015-03-27 2016-03-28 Vakcina zasnovana na rekombinantnom jeryl lynn 2 virusu zauški

Country Status (21)

Country Link
EP (1) EP3274447B1 (sr)
JP (2) JP2018510642A (sr)
KR (1) KR101970428B1 (sr)
CN (1) CN107667175A (sr)
AR (1) AR104271A1 (sr)
AU (1) AU2016242460B2 (sr)
BR (1) BR112017020643A2 (sr)
CA (1) CA2980847C (sr)
DK (1) DK3274447T3 (sr)
ES (1) ES2764677T3 (sr)
HR (1) HRP20200018T1 (sr)
HU (1) HUE047571T2 (sr)
IL (1) IL254698A0 (sr)
LT (1) LT3274447T (sr)
MX (1) MX2017012389A (sr)
PL (1) PL3274447T3 (sr)
PT (1) PT3274447T (sr)
RS (1) RS59774B1 (sr)
SG (1) SG11201707904XA (sr)
SI (1) SI3274447T1 (sr)
WO (1) WO2016157208A1 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107233576B (zh) * 2017-08-08 2020-02-07 江苏省农业科学院 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
CN111218473A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种拯救腮腺炎病毒的系统和方法
CN109593784A (zh) * 2019-01-14 2019-04-09 浙江大学 一种用于拯救腮腺炎病毒的系统及拯救方法
CN109628414B (zh) * 2019-01-14 2021-03-30 浙江大学 一种mRNA甲基转移酶缺陷型腮腺炎病毒及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729509B1 (en) * 1993-11-19 2004-05-06 GlaxoSmithKline Biologicals S.A. Vaccine against mumps containing a jeryl-lynn virus strain
AU761234B2 (en) * 1998-06-03 2003-05-29 Wyeth Holdings Corporation Novel methods for rescue of RNA viruses
EP1218499A2 (en) * 1999-08-02 2002-07-03 Wyeth RESCUE OF MUMPS VIRUS FROM cDNA
WO2004113517A2 (en) * 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
US9821052B2 (en) * 2009-07-31 2017-11-21 Seqirus UK Limited Reverse genetics systems

Also Published As

Publication number Publication date
BR112017020643A2 (pt) 2018-07-17
CN107667175A (zh) 2018-02-06
ES2764677T3 (es) 2020-06-04
CA2980847A1 (en) 2016-10-06
CA2980847C (en) 2020-03-24
AU2016242460B2 (en) 2019-04-18
JP2018510642A (ja) 2018-04-19
KR101970428B1 (ko) 2019-04-18
MX2017012389A (es) 2018-09-19
DK3274447T3 (da) 2020-01-27
PL3274447T3 (pl) 2021-07-19
AU2016242460A1 (en) 2017-10-19
WO2016157208A1 (en) 2016-10-06
WO2016157208A9 (en) 2017-03-16
JP2020074792A (ja) 2020-05-21
SI3274447T1 (sl) 2020-03-31
PT3274447T (pt) 2020-01-21
EP3274447A1 (en) 2018-01-31
HRP20200018T1 (hr) 2020-03-20
KR20170131659A (ko) 2017-11-29
AR104271A1 (es) 2017-07-12
SG11201707904XA (en) 2017-10-30
EP3274447B1 (en) 2019-10-16
IL254698A0 (en) 2017-11-30
HUE047571T2 (hu) 2020-04-28
LT3274447T (lt) 2020-02-10

Similar Documents

Publication Publication Date Title
ZA201804071B (en) Recombinant zika vaccines
HK1255847A1 (zh) 針對乙型肝炎病毒的疫苗
ZA201801035B (en) Vaccine compositions
RS63381B1 (sr) Vakcine protiv respiratornih virusa
SG10201913630YA (en) Zika virus vaccine
SI3393510T1 (sl) Cepivo proti virusu ZIKA
HK1250136A1 (zh) 具有改善的穩定性和免疫原性之疫苗組合物
GB201613191D0 (en) Zika virus vaccine
IL257025A (en) Recombinant orf virus vector
IL254698A0 (en) A vaccine based on the recombinant Jarl Lin mumps virus 2
GB201506041D0 (en) Avian vaccine
GB201504579D0 (en) Ovine vaccine
PT3393510T (pt) Vacina contra o vírus zika
GB201702193D0 (en) Hepatitis E virus vaccine
GB201521608D0 (en) Vaccine composition